Summary
Protara Therapeutics: End Of 2025 Proving Eventful Indeed
Protara Therapeutics (TARA) maintains strong momentum with TARA-002, showing durable, high complete response rates in NMIBC and promising efficacy in lymphatic malformations. TARA-002's 6-month complete response rate of 69% in BCG-naive NMIBC patients and 100% clinical success in lymphatic malformations reinforce its competitive positioning. With over two years of cash runway, TARA is well-capitalized to reach pivotal regulatory and clinical milestones, without near-term dilution risk.
Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC Patients Transcript
Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC Patients Transcript
Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations Transcript
Protara Therapeutics, Inc. ( TARA ) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations November 19, 2025 8:30 AM EST Company Participants Justine O'Malley - Senior Vice President of Investor Relations & Corporate Affairs Jesse Shefferman - Co-founder, CEO, President & Director Jacqueline Zummo - Co-Founder & Chief Scientific Operations Officer William Conkling - Chief Commercial Officer Conference Call Participants Jesse Jones Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Vishwesh Shah - TD Cowen, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Presentation Operator Hello, and welcome to the Protara Update Call. We ask that you please hold all questions until the completion of the formal remarks at which time you will be given instructions for the question-and-answer session.
Protara Therapeutics Inc. (TARA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Protara Therapeutics Inc. ever had a stock split?
Protara Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jesse Shefferman CEO | NASDAQ (NMS) Exchange | 74365U107 CUSIP |
| US Country | 28 Employees | - Last Dividend | 10 Jan 2020 Last Split | 22 Oct 2014 IPO Date |
Overview
Protara Therapeutics, Inc. is a pioneering force in the biopharmaceutical industry, focusing its efforts on the development of game-changing therapies aimed at treating cancer and rare diseases. Originally known as ArTara Therapeutics, Inc., the company underwent a rebranding in May 2020 and adopted its current name. With its headquarters in New York, New York, Protara is committed to pushing the boundaries of medicine through its clinical-stage programs. Its primary mission is to offer new hope and solutions to patients facing the challenges of lymphatic malformations and intestinal failure-associated liver disease.
Products and Services
- TARA-002: An investigational cell therapy developed by Protara Therapeutics. It is at the forefront of the company's research and is designed specifically for treating lymphatic malformations, a condition that can cause significant morbidity and impact the quality of life. This therapy represents a key example of Protara's commitment to addressing unmet medical needs through innovative treatments.
- Intravenous Choline Chloride: This investigational therapy is another example of Protara's dedication to rare diseases, specifically targeting intestinal failure associated liver disease (IFALD). IFALD is a critical condition that can arise from chronic intestinal failure, and Protara's development of intravenous choline chloride is aimed at providing a phospholipid substrate replacement therapy to address the underlying issues of this disease.
Contact Information
